glp-1 agonists and sglt2 inhibitors combination Receptor Agonist Therapy With Without in Patients With Type 2 Diabetes SGLT2 Inhibitors and GLP-1 Receptor
Description
With only 338 participants, a cardiovascular event rate of even 1 to 2% could easily be missed statistically
was supported by National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grants (P30 DK040561, U24 DK132733, and UE5 DK137285)
NSCs, neural stem cells
10.1186/s12944-017-0572-9 52
Other medications, such as metformin, Qsymia (phentermine/topiramate), Contrave (naltrexone/bupropion), and Xenical (orlistat), may also be prescribed as Ozempic alternatives, though they work differently
